CM
AVTX icon

Caption Management’s Avalo Therapeutics AVTX Stock Holding History

Caption Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-631,700
Closed -$9.43M – 1658
2026
Q1 		$9.43M Buy
631,700
+531,700
+532% +$8.31M 0.06% 355
2025
Q4 		$1.82M Buy
+100,000
New +$1.69M 0.01% 870

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Caption Management's AVTX Position: Q2 2026 in Review

Caption Management reduced its Avalo Therapeutics (AVTX) stake by 54% in Q2 2026, selling an estimated $3.87M and leaving 210,000 shares worth $3.88M. The position accounts for 0.02% of the portfolio, ranked #663.

Caption Management first reported a position in AVTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.79M in Q1 2026. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Caption Management held 210,000 shares of Avalo Therapeutics worth $3.88M as of Q2 2026.
  • Caption Management sold 245,000 Avalo Therapeutics shares in Q2 2026, an estimated $3.87M.
  • Avalo Therapeutics made up 0.02% of Caption Management's portfolio in Q2 2026, its #663 holding.
  • Caption Management first reported a position in Avalo Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Caption Management's Avalo Therapeutics position peaked at $6.79M in Q1 2026.
  • 125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.